

# 肝炎文献リスト\_2026年3月号

岡本宏明

2026-03-1

T and B cell targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques

Rahman S A, Gangadhara S, Gridley J, Mala U, Elrod E J, Bedard N, Bruneau J, Shoukry N H, Grakoui A, Amara R R

Hepatology 001732, Mar 6 [Epub ahead of print]

PMID:41790984

T細胞・B細胞を標的としたHCVワクチンの強力な免疫誘導効果

2026-03-2

Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer

Ju B, Liu Z, Yan H, Liu Y, Zhang L, Ge X, Wang X, Si Z, Zhou B, Fan Q, Wang M, Li Y, Lai W, Gan J, Wang H, Zhao J, Xia Y, Liao M, Zhang Z

Gut 2025-336641, Feb 9

PMID: 41663152

<https://doi.org/10.1136/gutjnl-2025-336641>

形質芽細胞由来HBs抗体の特徴とHBsAg二量体への結合メカニズム

2026-03-3

Experimental hepatitis E virus genotype 1 infection in three types of wild rodents

Zhang H, Wu Y, Wang H, Liu T, Liu X, Chen J, Sun Y, Xue L, Li C, Liu H, Chen H, Qi Y, An T, Wang L, Jin Z, Yu C, Yang X, Li Y, Li H, Xia C, Yin X, Wang L

PLoS Pathog 22(3): e1014050, 2026

PMID: 41849409

<https://doi.org/10.1371/journal.ppat.1014050>

3種の野生齧歯類におけるHEV(1型)感染の成立

2026-03-4

Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models

Hu J, Liu T, Klohn M, Freistaedter A, Toprak E, Chi H, Gomer A, Pottkaemper L, Jordan P, Yang X, Zhang H, Becker J, Nkongolo S, Lohmann V, Steinmann E, Wang L, Dao Thi V L

Gut 2025-336714, Mar 6 [Epub ahead of print]

PMID: 41791851

<https://doi.org/10.1136/gutjnl-2025-336714>

核酸アナログ bemnifosvir はスナネズミでHEVの複製を抑制する

2026-03-5

EIF4H and YBX1 are essential host factors for hepatitis E virus replication and pathogenesis

Ju X, Dong L, Liu T, Zhang F, Sun X, Schwoerer M P, Ren W, Gong M, Ploss A, Qin W, Wu X, Wang L, Ding Q

Proc Natl Acad Sci U S A 123(10): e2529289123, 2026

PMID:41779781

EIF4HとYBX1はHEV増殖と病態形成に必須の宿主因子である

2026-03-6

CDK8 and CDK19 mediator kinases are required for hepatitis delta virus replication

Prawira A, Hilleke M, Chen M, Roninson I B, Bartenschlager R, Urban S, Ni Y

Hepatology 001690, Feb 10 [Epub ahead of print]

PMID:41665877

[HDV 複製に必須の CDK8・CDK19 キナーゼの役割](#)

2026-03-7

Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation

Lucifora J, Negro F

Hepatology 001705, Feb 13 [Epub ahead of print]

PMID: 41632947

<https://doi.org/10.1097/hep.0000000000001705>

[HDV 複製開始の「ニワトリか卵か」問題に迫る](#)

2026-03-8

Hepatitis B vaccination: A remarkable success story that must continue

Lok A S, Ward J W, Chang M H, Cohen C

Gastroenterology 170(3):447-51, 2026

PMID: 41241364

<https://doi.org/10.1053/j.gastro.2025.10.295>

[B 型肝炎ワクチンの功績と継続の重要性](#)

2026-03-9

The crucial but insufficient role of E2s domain's residues 490 and 492 in determining the host tropism of hepatitis E virus

Tang Z M, Yang C Y, Wen G P, Liu C, Ying D, Huang Y, Yu Z H, Li M Y, Wang S L, Chen Z H, Liu J F, Fang M J, Wang Y B, Zhang J, Gu Y, Yu H, Li S W, Zheng Q B, Xia N S, Zheng Z Z

Nat Commun 026-69125-5, Feb 9 [Epub ahead of print]

PMID: 41663378

<https://doi.org/10.1038/s41467-026-69125-5>

[HEV の宿主域決定における E2s ドメイン 490・492 残基の重要だが限定的な役割](#)

2026-03-10

Hepatitis B virus ribonuclease H inhibitors: Coming of age?

Walden H M, Tsimpili H, Woodson M E, Zoidis G, Tavis J E

Antiviral Res 249:106396, 2026

PMID: 41856207

<https://doi.org/10.1016/j.antiviral.2026.106396>

[HBV RNase H 阻害剤は実用段階に到達したか](#)

2026-03-11

Prospects for leveraging knowledge on ISG and NF- $\kappa$ B effector functions into anti-HBV therapies

Zhao K, Xia Y

Antiviral Res 249:106397, 2026

PMID:41856208

[ISG および NF- \$\kappa\$ B の知見を活かした新規抗 HBV 治療の展望](#)

2026-03-12

Single-cell hepatitis B sequencing reveals distinct viral infection events consistent with superinfection

Mani M, Clipman S J, Bailey J R, Sterling R K, Sulkowski M S, Anderson M, Olivo A, Belluccini G, Cloherty G, Ribeiro R M, Thio C L, Balagopal A

J Infect Dis 191(12):2181-2191, Mar 20 [Epub ahead of print] PMID:41856168

[単一細胞解析で明らかになった HBV の重複感染様の感染動態](#)

2026-03-13

Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175/mp7 challenge in interferon-receptor-deficient mice

Chung Y-J, Oh H-S, Kim S-O, Hong S P

Virology 619:110883, 2026

[新規不活化 A 型肝炎ワクチン GMAI-02 の防御効果\(マウスモデル\)](#)

2026-03-14

The evolution of *in vitro* culture systems for the study of hepatitis E virus infection

Brown H M, Meng X-J

Virology 619:110886, 2026

[HEV 研究における培養系の進化](#)

2026-03-15

Spontaneous reactivation of resolved HBV infection in the absence of immunosuppression: case report and literature review

Ozturk Cerik H, Aldemir O

Diagn Microbiol Infect Dis 111(3):116675, 2025 PMID:39754919

[免疫抑制なしで生じた HBV 自然再活性化の症例報告](#)

2026-03-16

HCV infection induces ubiquitin-dependent degradation of LATS1, inactivating the Hippo pathway and upregulating transcription of the CYR61 and CTGF genes

Septianastiti M A, Matsui C, Xu Z, Puspitasari F, Adyaksa D N M, Deng L, Abe T, Shoji I

J Gen Virol 107(2):002221, 2026 PMID: 41642640

<https://doi.org/10.1099/jgv.0.002221>

[HCV 感染は LATS1 分解を介して Hippo 経路を抑制する:腫瘍関連遺伝子発現亢進の新たな仕組み](#)

2026-03-17

From discovery to therapy: The role of HSPB1 in HBV persistence ([Editorial] to 89881)

Schwartz R E, Tarr A W, Brown R J P

J Hepatol 84(3):487-9, 2026 PMID: 41349615

<https://doi.org/10.1016/j.jhep.2025.11.026>

[HBV 持続感染における HSPB1 の役割:基礎から治療応用へ](#)

2026-03-18

Detection and characterization of hepatitis B virus double-stranded linear DNA-derived covalently closed circular DNA in chronic hepatitis B patients

Liu H N, Kim E, Sun N, Wang Z, Nguyen T, Shieh F S, Liu Y, Ghany M G, Chung R T, Sterling R K, Lin S Y, Guo H, Lau D T Y, Su Y H

PLoS Pathog 22(2): e1013999, 2026

PMID: 41734230

<https://doi.org/10.1371/journal.ppat.1013999>

慢性 B 型肝炎患者における dsL DNA 由来 cccDNA の検出と解析

2026-03-19

Development of a fully automated, high-throughput molecular assay for detection of rat hepatitis E virus in routine diagnostics

Panajotov J, Giersch K, Pfluger L S, Norz D, Grunwald M, Tang H T, Kaiser M, Pischke S, Ulrich R G, Pfefferle S, Schulze Zur Wisch J, Corman V M, Aepfelbacher M, Johne R, Lutgehetmann M

J Med Virol 98(2): e70824, 2026

PMID: 41660728

<https://doi.org/10.1002/jmv.70824>

ラット HEV を迅速検出する全自動高感度検査法の開発

2026-03-20

Global, regional, and national time trends in incidence for hepatitis A, 1990-2021: A systematic analysis for the global burden of disease 2021 study

Huang A, Xu X, Zhang Q

J Med Virol 98(2): e70838, 2026

PMID:41656937

30 年間(1990~2021 年)でみた A 型肝炎の世界・地域別動向

2026-03-21

Novel long-read sequencing method for characterisation of hepatitis B transcripts show high expression of chimeric HBV/Human RNA

Stenback J B, Ringlander J, Andersson M, Thomsen J H D, Abrahamsson S, Rydell G E, Lindh M

Liver Int 46(3): e70521, 2026

PMID: 41684309

<https://doi.org/10.1111/liv.70521>

ロングリード解析で明らかになった HBV/ヒト融合 RNA の高発現

2026-03-22

Indeterminate phase/grey zone of chronic hepatitis B: Clinical features, outcomes and molecular insights

Franze M S, Pollicino T, Pawlotsky J M, Leroy V, Raimondo G, Amaddeo G

Liver Int 46(3): e70545, 2026

PMID: 41665535

<https://doi.org/10.1111/liv.70545>

慢性 B 型肝炎「不確定期」の臨床像と転帰、分子背景

2026-03-23

Mechanistic insights into CAM-induced disruption of HBV capsids revealed by all-atom MD simulations

Perez-Segura C, Goh B C, Hadden-Perilla J A

PLoS Pathog 22(2): e1013566, 2026

PMID: 41662449

<https://doi.org/10.1371/journal.ppat.1013566>

カプシド集合モジュレーター(CAM)によるHBVカプシド破壊の分子機序

2026-03-24

Advances in rapid nucleic acid diagnostics for hepatitis B and C viruses: A comprehensive review

Ho H Y, Dai C Y, Feng I J, Chen Y H, Yu M L, Lin C H, Yu L S

Rev Med Virol 36(2): e70110, 2026

PMID:41656498

HBV・HCV 迅速核酸診断の最新動向

2026-03-25

Post-to pretreatment ratio of serum CXCL10 level predicts short-term liver function outcome in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy

Suzuki T, Matsuura K, Tahata Y, Hikita H, Enomoto M, Tsuchiya A, Miki D, Yatsunami H, Kuroda H, Yamashita T, Yoshiji H, Tamaki N, Mawatari S, Miyaaki H, Asahina Y, Hiasa Y, Uchida Y, Nakamoto Y, Takami T, Kodama T, Takehara T

Hepatol Res 70139, Feb 9 [Epub ahead of print]

PMID: 41661712

<https://doi.org/10.1111/hepr.70139>

CXCL10 変化率でみる DAA 治療後の肝機能回復予測

2026-03-26

Development of a novel human hepatoma cell line supporting the replication of a recombinant HBV genome with a reporter gene

Kawase S, Shimakami T, Kuroki K, Murai K, Funaki M, Yoshita M, Kakuya M, Suzuki R, Li Y-Y, Gantumur D, Kawane T, Matsumori K, Nio K, Kawaguchi K, Takatori H, Honda M, Yamashita T

Viruses 18(2):187, 2026

<https://doi.org/doi:10.3390/v18020187>

組換えHBVの複製を可能にする新規肝癌細胞株の樹立

2026-03-27

Indeterminate-grey zone of HBeAg-negative chronic hepatitis B is associated with a higher risk of hepatocellular carcinoma compared to HBeAg-negative chronic infection—A systematic review and meta-analysis

Syrigou R, Tiganiti D, Kintzoglakis K, Lekakis V, Karagiannakis D

Livers 6(1):9, 2026

<https://doi.org/10.3390/livers6010009>

HBe 抗原陰性慢性 B 型肝炎「不確定期」は肝癌リスクが高い

2026-03-28

Recent progress in structures and functions of hepatitis C virus NS3/4A proteins

Huang K, Zhang M, Huang Y, Chen Z

Viruses 18(2):233, 2026

<https://doi.org/10.3390/v18020233>

HCV NS3/4A タンパク質の構造と機能の最新知見

2026-03-29

Challenges and solutions in pgRNA measurement: Toward improved monitoring of hepatitis B therapy

Zhu Z, Wu J, Li J, Wu T

Pathogens 15(2):153, 2026

<https://doi.org/10.3390/pathogens15020153>

B 型肝炎治療モニタリングにおける pgRNA 測定の課題と克服法

2026-03-30

Stability under different stress treatments of a virus-like particle vaccine based on a recombinant hepatitis E vaccine

Qi Z, Guo S, Li H, Xia X, Qi S, Tang E, Zhou Z, Wang Y, Yu C, Wu X, Wu H

Pharmaceutics 19(2):269, 2026

<https://doi.org/10.3390/ph19020269>

組換え HEV VLP ワクチンの各種ストレス処理下での安定性

2026-03-31

Hepatocyte-targeted drug delivery strategies for chronic hepatitis B: Overcoming delivery barriers toward functional cure

Elbehiry A, Aldubaib M

Pharmaceutics 18(2):212, 2026

<https://doi.org/10.3390/pharmaceutics18020212>

慢性 B 型肝炎に対する肝特異的薬剤送達戦略

2026-03-32

Incidence and characteristics of HBV reactivation-related events following HBsAg seroclearance: Long-term follow-up of a population-based cohort in Japan

Yamasaki K, Shirahama S, Yasaka T, Yamaguchi S, Mizokami M, Tanaka J, Okamoto H, Yatsunami H

Hepatol Res 70146, Feb 26 [Epub ahead of print]

PMID: 41748328

<https://doi.org/10.1111/hepr.70146>

HBs 抗原陰性化後の HBV 再活性化イベント: 日本人コホート長期追跡

2026-03-33

Antiviral therapy reduces HCC and cirrhosis risk in Chinese chronic hepatitis B patients with mildly elevated ALT

Wang J, Zhang Z, Zhu L, Fan T, Xiong Y, Zhang S, Jiang C, Yin S, Tong X, Xia J, Yan X, Yao R, Shi Y, Liu X, Zhu C, Wu C, Huang R

Clin Gastroenterol Hepatol 2026.02.008,

Feb 17 [Epub ahead of print]

PMID:41713830

ALT 値軽度上昇慢性 B 型肝炎患者における抗ウイルス療法の HCC・肝硬変抑制効果

2026-03-34

Towards HDV elimination through HBV vaccination: Global strategies, challenges, and policy gaps

Batbold E, Dashdorj N, Zoulim F, Bartosch B

Vaccines 14(2):179, 2026

<https://doi.org/10.3390/vaccines14020179>

HBV ワクチンによる HDV 排除戦略

2026-03-35

Hepatitis E in wildlife: Emerging threats to human health

Veskovic Moracanin S M, Kureljusic B I, Maletic J, Kureljusic J M, Jezdimirovic N V, Vasic A M, Milovanovic B Z, Savic B M

Vet Sci 13(2):160, 2026

<https://doi.org/10.3390/vetsci13020160>

野生動物に広がる HEV とヒトへの脅威

2026-03-36

Development of a hypersensitive digital ELISA system for hepatitis B core antigen

Nakaya Y, Hasegawa T, Hoshi Y, Onomura D, Yamagata T, Okamoto H, Murata K, Kato M

Anal Bioanal Chem 026-06338-z, Jan 22 [Epub ahead of print] PMID:41572036

高感度デジタル ELISA による HBc 抗原測定系の開発

2026-03-37

Acute severe hepatitis B virus infection in previously vaccinated patient during acalabrutinib treatment

Rojek L, Wnuk-Lipinski T, Marek I, Grabowski H, Adrych K

Emerg Infect Dis 32(2):287-9, 2026

PMID: 41714905

<https://doi.org/10.3201/eid3202.251111>

ワクチン既接種者に生じた重症急性 B 型肝炎:アカラブルチニブ治療下での発症

2026-03-38

The impact of hepatitis B virus on the tumor microenvironment of hepatocellular carcinoma and therapeutic strategies

Li X, Wu Z, He Z, Xu Y, Xie W, Huang S, Chen L, Gao Z, Tang S, Gao X, Tian H

J Gastroenterol Hepatol 70309, Feb 24 [Epub ahead of print] PMID: 41734811

<https://doi.org/10.1111/jgh.70309>

HBV が肝細胞癌の腫瘍微小環境に与える影響と治療戦略

2026-03-39

Impact of a naturally occurring hepatitis B virus genotype D-specific core-promoter mutation on viral replication

Kanai M, Shin I T, Date T, Sakai A, Mizokami M, Sugiyama M

J Gen Virol 107(2):002225, 2026

PMID: 41712434

<https://doi.org/10.1099/jgv.0.002225>

HBV(D 型)特異的コアプロモーター自然発生変異がウイルス増殖に与える影響

2026-03-40

Immunogenicity of two versus three doses of hepatitis B vaccine when administered to children aged 2-18 months: a randomized clinical trial

Kegbevi K B, Febriani Y, Sauvageau C, Ursu M M, Quach C, Desjardins M, Bestman-Smith J, Gilca V, Brousseau N

J Infect Dis jia122, Feb 25 [Epub ahead of print] PMID: 41739814

<https://doi.org/10.1093/infdis/jia122>

乳幼児における B 型肝炎ワクチン 2 回接種と 3 回接種の免疫原性比較

2026-03-41

Hepatitis B vaccination coverage and vaccine-associated immunity among US-born children and adolescents: NHANES 2017-2020

Lin Y, Hou Y, Chen Z, Zhang Y, Agins B, She Y, Jiang H

J Med Virol 98(2): e70848, 2026 PMID:41721575

米国 NHANES (国民健康栄養調査) データからみた小児・思春期の B 型肝炎ワクチン効果

2026-03-42

Hepatic steatosis inhibits hepatitis B virus replication by promoting miR-122-5p-SOX4

Ren G, Jia K, Yi S, Yin S, Huang G, Zhu Y

J Viral Hepat 33(3): e70151, 2026 PMID:41721392

脂肪肝は HBV 増殖を抑制する: miR-122-5p-SOX4 経路の関与

2026-03-43

Hepatitis E infection in patients with inflammatory bowel diseases: A systematic review and meta-analysis

Kogias D, Kouklakis G, Papadopoulos V

J Viral Hepat 33(3): e70152, 2026 PMID:41721452

炎症性腸疾患 (IBD) 患者における HEV 感染: 系統的レビューとメタ分析

2026-03-44

Regional comparisons of the prevalence and socioeconomics of hepatitis delta virus in two Southern California Counties

Pak K, Leng M, Nguyen J, Moussa K, Gish R, Han S H, Pockros P

J Viral Hepat 33(3): e70155, 2026 PMID:41704203

南カリフォルニア 2 郡における HDV 有病率と社会経済的背景

2026-03-45

Comparing specificity and seroconversion sensitivity among major blood screening assays for human immunodeficiency virus and viral hepatitis

Chaves M, Schaetzl M, Pessl F

Vox Sang 70222, Feb 17 [Epub ahead of print] PMID: 41702683

<https://doi.org/10.1111/vox.70222>

HBV・HCV・HIV スクリーニング検査の性能比較: Roche Elecsys vs. Abbott Alinity

2026-03-46

Long-term mortality following hepatitis C cure in a real-world multinational cohort

Ji F, Tran S, Toyoda H, Enomoto M, Ogawa E, Suzuki T, Huang C F, Wong Y J, Chuma M, Uojima H, Atsukawa M, Hsu Y C, Jun D W, Nozaki A, Tseng C H, Ishigami M, Honda T, Trinh H, Watanabe T, Abe H, Preda C, Lee D H, Ishikawa T, Haga H, Liang J, Takahashi H, Vutien P, Landis C, Li J, Takaguchi K, Senoh T, Huang R, Wong G L, Wong V W, Lam C P, Huang D Q, Asai A, Ye Q, Do A T, Do S, Itokawa N, Nakamuta M, Nomura H, Kajiwara E, Azuma K, Dohmen K, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yoon E L, Ahn S B, Jung J H, Kim S E, Kim G A, Jeong S W, Oh H, Yasuda S, Gao X, Zhao Y, Liu Y, Zhao C, Okubo T, Jun M J, Alecu R I, Tay W X, Devan P, Liu J K, Kozuka R, Vargas-Accarino E, Inoue K, Maeda M, Eguchi Y, Ueno Y, Chuang W L, Huang J F, Dai C Y, Henry L, Cheung R, Yeh M L, Tsai P C, Buti M, Lim S G, Wu C, Yuen M F, Furusyo N, Hayashi J, Yu M L, Tanaka Y, Nguyen M H

Liver Int 46(3): e70561, 2026

PMID:41724904

[C型肝炎治癒後の長期死亡リスク:多国籍リアルワールド研究](#)

2026-03-47

Predictive value of sustained virologic response at week 4 in patients with hepatitis C virus infection treated with sofosbuvir/velpatasvir

Landry G, Sulkowski M, Feld J J, Reau N, Scherbakovsky S, Black F, Hernandez C, Mercier R C, Ni L, Bourliere M, Mangia A

Viruses 18(2):269, 2026

PMID: 41754612

<https://doi.org/10.3390/v18020269>

[SOF/VEL 治療における 4 週時点 SVR の予測的意義](#)

2026-03-48

Alpha-1B glycoprotein is a novel hepatocyte-derived host factor associated with in vitro inhibition of HBV replication and hepatocellular carcinoma progression

Lyu J, Nosaka T, Murata Y, Akazawa Y, Tanaka T, Takahashi K, Naito T, Ohtani M, Zhang L, Nakamoto Y

Cancers (Basel) 18(4):662, 2026

PMID: 41749914

<https://doi.org/10.3390/cancers18040662>

[アルファ 1B 糖タンパク質:HBV 増殖と肝癌進展を抑える新規因子](#)

2026-03-49

Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD

Wu W, Gao Q, Hai S, Li X, Yu B, Hu J, Xu F, Zheng X, Wang Y, Danzeng A, Zhang B H, Ning Q, Wang X

Gut 2026-338065, Mar 3 [Epub ahead of print]

PMID: 41775516

<https://doi.org/10.1136/gutjnl-2026-338065>

[Rab7 依存性 STING 分解の障害は HBV 複製を抑えるが、MASLD 合併慢性 B 型肝炎の病勢を悪化させる](#)

2026-03-50

Azathioprine inhibits hepatitis A virus replication in vitro

Kanda T, Sasaki-Tanaka R, Abe H, Yokoo T, Sakamaki A, Hayashi K, Kamimura H, Kamimura K, Masuzaki R, Kogure H, Okamoto H, Terai S

Pathogens 15(3):249, 2026 <https://doi.org/10.3390/pathogens15030249>

アザチオプリンは HAV 増殖を抑制する

2026-03-51

Diagnostic value of LPRI for assessing advanced liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease

Wang M, Chen H, Yang J, Huang X, He R, Pei B, Wu X, Kang Y, Xu L

BMC Gastroenterol 026-04645-4, Feb 4 [Epub ahead of print] PMID: 41639646

<https://doi.org/10.1186/s12876-026-04645-4>

慢性 B 型肝炎・NAFLD 合併例における線維化診断指標としての LPRI の有用性

2026-03-52

Assessing the sensitivity and predictive value of wastewater in detection of hepatitis A cases in San Diego County

Ramesh A, Goyal R, Stous S, Thomas H R, Shah S, Aronoff-Spencer E, Beatty M E, Martin N K

PLoS One 21(2): e0342229, 2026

PMID: 41706668

<https://doi.org/10.1371/journal.pone.0342229>

下水サーベイランスによる A 型肝炎検出の有用性(米国サンディエゴ郡)

2026-03-53

Clinical characteristics of hospitalized patients with hepatitis E virus infection in Poland: a multi-centre retrospective study

Parfieniuk-Kowerda A, Jaroszewicz J, Grabarczyk P, Zarebska-Michaluk D, Sikorska K, Piekarska A, Berkan-Kawinska A, Koziulewicz D, Pawlowska M, Pazgan-Simon M, Sobala-Szczygiel B, Zielinski P, Rydzewski A, Serwacka A, Tomasiewicz K, Budziszewska B K, Flisiak R

Adv Med Sci 71(1):75-82, 2026

PMID:41748069

ポーランドにおける E 型肝炎入院患者の臨床像: 多施設後ろ向き研究

2026-03-54

A transfusion-transmitted chronic hepatitis E virus infection after allogeneic bone marrow transplantation with viral clearance following immunosuppression tapering

Sato K, Kazumoto H, Tanaka A, Sakata H, Sunohara S, Kazama S, Kaiume H, Mori H, Ueki T

Intern Med 6903-25, Mar 3 [Epub ahead of print]

PMID: 41780982

<https://doi.org/10.2169/internalmedicine.6903-25>

同種骨髄移植後に発症した輸血由来慢性 E 型肝炎:免疫抑制剤減量によりウイルス消失

2026-03-55

Hepatitis B vaccination at birth: Safety, effectiveness, and public health benefit

Ulrich A K, Fleming D F, Smith E A, Anderson C J, Mehr A J, Redepenning S G, Stoddart C J, Moat L E, Walensky R P, Lackritz E M

Pediatrics 2025-075783, Feb 5 [Epub ahead of print] PMID: 41639943

<https://doi.org/10.1542/peds.2025-075783>

出生時 B 型肝炎ワクチン接種の安全性と有効性、公衆衛生的意義

2026-03-56

Molecular characterization of hepatitis B virus genotypes A and D among inmates and blood donors in Northeastern Kenya

Odallo V B, Aluora O P, Bulimo W, Gachara G

PLoS One 21(2): e0336726, 2026 PMID: 41701752

<https://doi.org/10.1371/journal.pone.0336726>

ケニア北東部の受刑者・献血者における HBV(A 型・D 型)の分子疫学

2026-03-57

Long-term HBsAg clearance, relapse, and safety following tenofovir or entecavir discontinuation in non-cirrhotic, HBeAg-negative chronic hepatitis

Sattayalertyanyong O, Bandidniyamanon W, Limsrivilai J, Chotiyaputta W, Nimanong S, Tanwadee T

Sci Rep 026-40972-y, Feb 24 [Epub ahead of print] PMID: 41735396

<https://doi.org/10.1038/s41598-026-40972-y>

非肝硬変・HBe 抗原陰性慢性 B 型肝炎における核酸アナログ中止後の HBs 抗原消失・再燃・安全性

2026-03-58

Serum Mac-2 binding protein glycosylation isomer in predicting hepatocellular carcinoma occurrence among patients with direct-acting antiviral-induced HCV cure

Chang Y P, Chen Y C, Su T H, Huang S C, Tseng T C, Chen P J, Liu C J, Kao J H, Liu C H

Sci Rep 16:5757, 2026 PMID: 41554947

<https://doi.org/10.1038/s41598-026-36809-3>

DAA 治療後の C 型肝炎治癒患者における肝細胞癌発症予測マーカーとしての M2BPGi

2026-03-59

Expression of CD38<sup>+</sup>CD8<sup>+</sup> T cells in hepatitis B-related acute-on-chronic liver failure and its prognostic value

Li J, Li H, Du S, Kang L, Liu M, Gao L, Gao Y

Sci Rep 16:6609, 2026 PMID: 41611910

<https://doi.org/10.1038/s41598-026-37404-2>

HBV 関連 ACLF における CD38<sup>+</sup> CD8<sup>+</sup> 細胞と予後との関連

2026-03-60

A computational structural analysis of host insertions in the polyproline region of the hepatitis E virus pORF1 polyprotein

Jeanne N, Paronetto O, Dimeglio C, Abravanel F, Lhomme S, Brut M, Izopet J

Viruses 18(3):341, 2026

<https://doi.org/10.3390/v18030341>

HEV pORF1 ポリタンパクのポリプロリン領域における宿主配列挿入の構造解析(計算科学的検討)

2026-03-61

Low transmission rate of hepatitis E virus by transfusion of hepatitis E virus RNA-positive blood products

Sommer-Strunck N M, Plumers R, Vollmer T, Rupp J, Glessing P, Gorg S, Hennig H, Juhl D

Transfus Med Hemother 53(1):3-12, 2026

PMID: 41684702

<https://doi.org/10.1159/000548743>

HEV RNA 陽性血液製剤による HEV の輸血感染率は低い

2026-03-62

High intrahepatic cccDNA in resolved HBV infection: Insights from living donor liver transplantation with anti-HBc-positive grafts

Bae S K, Akamatsu N, Ichida A, Nishioka Y, Inagaki Y, Miyake N, Takamoto T, Kawaguchi Y, Tamura S, Arita J, Kaneko J, Otsuka M, Tanaka Y, Yotsuyanagi H, Moriya K, Hasegawa K

J Gastroenterol Hepatol 70324, Mar 11 [Epub ahead of print] PMID: 41814529

<https://doi.org/10.1111/jgh.70324>

HBV 既感染でも肝内 cccDNA は高値: 生体肝移植からの知見

2026-03-63

Analysis of the epidemiological trends of hepatitis A and E in Zhejiang Province and clinical characteristics of severe patients

Yue X, Gao J, Shao Z, Wu L, Yu J, Miao Z, Pan H

BMC Infect Dis 026-12894-7, Feb 17 [Epub ahead of print] PMID: 41703477

<https://doi.org/10.1186/s12879-026-12894-7>

中国浙江省における A 型・E 型肝炎の疫学動向と重症例の臨床像

2026-03-64

Elevated risk of hepatitis E virus infection among sheep smallholders in Xinjiang, China

Xu W T, Ding Y S, Chen Y G, Feng Y H, Li J, Jin J G, Wei X N, Wu F, Wang X Y, Dang X T, Zhang G W, Xiang X Y, Li F Y, Zhang W B, Wu J Y

One Health 22:101361, 2026

PMID: 41757272

<https://doi.org/10.1016/j.onehlt.2026.101361>

中国新疆ウイグル自治区の羊飼育農家で HEV 感染リスクが高い

2026-03-65

Global seroprevalence of hepatitis E among people living with HIV: a systematic review and meta-analysis

Magri M C, Manchiero C, Dantas B P, Bernardo W M, Abdala E, Tengan F M

Epidemiol Rev mxag003, Mar 4 [Epub ahead of print] PMID:41778828

HIV 感染者における HEV 抗体保有率の世界的実態: 系統的レビューとメタ分析

2026-03-66

Challenges in diagnosing and managing hepatitis E in transplant recipients: A case report

Martins A C, Pimenta G, Mascarenhas A, Verissimo R, Querido S, Weigert A

Case Rep Transplant 2026:3747751, 2026 PMID: 41695026

<https://doi.org/10.1155/crit/3747751>

移植患者における E 型肝炎診療の難しさ: 症例報告

2026-03-67

Colorimetric loop-mediated isothermal amplification for the rapid and visual detection of hepatitis B virus

Khan S J, Khamai L, Kham-Kjing N, Khamduang W, Hongjaisee S

Sci Rep 16:2625, 2026 PMID: 41521246

<https://doi.org/10.1038/s41598-026-35503-8>

HBV を迅速・目視で検出する比色 LAMP 法

2026-03-68

Re-evaluating the diagnostic value of  $\alpha$ -fetoprotein for hepatocellular carcinoma in the direct-acting antiviral era

Takeda Y, Imamura H, Ichida H, Yoshioka R, Mise Y, Saiura A

Cancer 132(4): e70308, 2026 PMID:41665927

DAA 時代における AFP の肝癌診断マーカーとしての再評価

2026-03-69

Unexpectedly low prevalence of hepatitis delta virus infection in Southern Viet Nam

Nguyen T, Vo V H, Le L, Luong A B, Nguyen C D, Quach P T, Trinh T T, Phan S T, Cao T N, Mai T B C, Hoang V A, Bui H H, Maldarelli F

Sci Rep 16:3307, 2026 PMID: 41476105

<https://doi.org/10.1038/s41598-025-33268-0>

ベトナム南部で HDV 感染率が予想外に低い

2026-03-70

Occult hepatitis B virus infection among hepatitis B surface antigen negative vaccinated healthcare workers in East Gojjam zone hospitals

Aduugna A, Abebaw D, Malik T, Jemal M

Sci Rep 16:4701, 2026 PMID: 41495433

<https://doi.org/10.1038/s41598-025-34788-5>

HBs 抗原陰性ワクチン接種医療従事者にみられた occult HBV 感染

2026-03-71

Association of ANXA3 methylation with clinical outcomes of glucocorticoid therapy in patients with hepatitis B virus-related acute-on-chronic liver failure

Wang Z, Zhang F, Zhu H, Tian Z, Xu M, Fan Y, Gao S, Wang K

Sci Rep 16:7235, 2026

PMID: 41639312

<https://doi.org/10.1038/s41598-026-37687-5>

HBV 関連 ACLF 患者における ANXA3 メチル化とステロイド治療効果の関連

2026-03-72

Association between LDL-R (exon 8 C.1171 G > A) polymorphisms and response to antiviral therapy in hepatitis C virus infection

Shikhoun M E H, Ibrahim H A M, Abeed A A O

Sci Rep 16:7473, 2026

PMID: 41720870

<https://doi.org/10.1038/s41598-026-38468-w>

LDL 受容体遺伝子多型と C 型肝炎抗ウイルス治療の関連

2026-03-73

Anti-HCV NS2-3 potential of selected plant bioactive compounds revealed by docking, simulation and DFT

Mboto C I, Mbim E N, Edet U O, Lugos M, Abdalla M, Ndifon W O, Ebenso E E, Udo S I, Egharevba H O, George U E, El-Sayed M H, Abdalla S F

Sci Rep 025-18577-8, Feb 19 [Epub ahead of print]

PMID: 41714668

<https://doi.org/10.1038/s41598-025-18577-8>

植物由来化合物の HCV NS2-3 阻害作用:ドッキングとシミュレーション解析

2026-03-74

Changes in the liver fibrosis of patients who develop hepatocellular carcinoma after a sustained virologic response to hepatitis C virus infection

Toyoda H, Nozaki A, Hiraoka A, Itobayashi E, Uojima H, Abe H, Takaguchi K, Atsukawa M, Itokawa N, Matsuura K, Kojima M, Ishikawa T, Watanabe T, Mikami S, Tsuji K, Ohama H, Tada F, Tsutsui A, Okubo T, Arai T, Nakamuta M, Imai M, Tanaka K, Tada T, Nakamura S, Shimada N, Kumada T

J Med Virol 98(3): e70865, 2026

PMID:41788051

SVR 後に肝癌を発症した C 型肝炎患者の線維化変化

2026-03-75

Prolonged intrahepatic cholestasis after acute hepatitis E infection: A case series and genetic analysis

Fraga M, Kasmi S, Weber S N, Liebe R, Sempoux C, Saadat A, Fellay J, Kenngott-Kelber S, Zimmer V, Lammert F, Krawczyk M, Jungst C

J Viral Hepat 33(4): e70156, 2026

PMID: 41797682

<https://doi.org/10.1111/jvh.70156>

急性 E 型肝炎後に遷延する肝内胆汁うっ滞: 症例集積と遺伝子解析

2026-03-76

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in lowering the risk of HCC development in patients with CHB

Kang S H, Yim H J, Han S K, Yim S Y, Kim T H, Lee Y S, Shin S K, Jung Y K, Kim M Y, Kim J H, Seo Y S, Kwon O S, Yeon J E, Baik S K

J Gastroenterol Hepatol 70326, Mar 8 [Epub ahead of print] PMID:41797216

TAFとTDFの比較:慢性B型肝炎患者の肝癌発症リスク低減効果

2026-03-77

Investigation of common foodborne virus contamination in commercially available fresh fruits, vegetables, and their ready-to-eat products in Shijiazhuang, China

Wang Y, Xiang J, Wang J, Sun X, Hu X, Xu X, Wang J

Food Environ Virol 18(1):11, 2026 PMID:41790333

市販生鮮食品におけるウイルス汚染の調査(中国・石家荘)

2026-03-78

Evaluation of HBsAg and anti-HBs coexistence: Authenticity and contributing factors

Xu H, Yang X, Chen L, Yao X, Xu Y, Wang Q

J Med Virol 98(3): e70862, 2026 PMID:41787947

HBs抗原とHBs抗体の共存の評価: その背景と要因

2026-03-79

KAT8: A promising biomarker for the prognosis of hepatitis B virus-related acute-on-chronic liver failure

Wang X, Wang W, Huang L, Yang Y, Lu W, Wu Y, Xu M, Chen Y

J Gastroenterol Hepatol 70313, Mar 6 [Epub ahead of print] PMID:41792982

KAT8: HBV関連ACLFでの予後予測の有望なバイオマーカー

2026-03-80

Prevalence, clinical presentation and outcome of hepatitis B patients with indeterminate phase: A systematic review and meta-analysis

Li J, Xu X, Liu J, Li M, Issa R, Bai X, Kam L Y, Stave C D, Ni W, Rui F, Zhu Y, Ma X, Gu Q, Pan Y, Wu C, Nguyen M H

J Viral Hepat 33(4): e70161, 2026 PMID:41761832

不確定期B型肝炎の頻度・臨床像・転帰: 系統的レビューとメタ分析

2026-03-81

Current global estimates, risk factors, and knowledge gaps for Hepatitis E virus (HEV): A scoping review

Ahmed M K, Maroofi H, Blunt M, Labrique A, Kirkwood C, Vannice K, Talaat K R, Lynch J, Kmush B L

PLoS Negl Trop Dis 20(3): e0013980, 2026 PMID: 41811926

<https://doi.org/10.1371/journal.pntd.0013980>

世界におけるE型肝炎の実態と知識ギャップ

2026-03-82

Epigenetic regulation of microRNA expression by hepatitis B virus pre-S2 mutant promotes hepatocellular carcinoma tumorigenesis

Lin Y T, Jeng L B, Shih F Y, Teng C F

Liver Int 46(4): e70582, 2026

PMID:41797438

[HBV Pre-S2 変異が miRNA を介して肝癌発生を促進](#)

2026-03-83

Prevalence and risk factors of elevated alanine aminotransferase (ALT) in 2382 treatment-naive HBV/HDV co-infected patients

Kamal H, Jargalsaikhan G, Enkhtaivan S, Lindahl K, Hagstrom H, Bruce D, Ingre M, Dashtserenx B, Lkhagva-Ochir O, Ulziibadrakh T, Bungert A, Wedemeyer H, Dashdorj N B, Aleman S

Liver Int 46(4): e70559, 2026

PMID: 41749331

<https://doi.org/10.1111/liv.70559>

[未治療 HBV/HDV 重複感染での ALT 上昇頻度と危険因子](#)

2026-03-84

Vaccines at the heart of hepatitis elimination: Insights from the ESCMID Study Group for Viral Hepatitis (ESGVH)

Sandulescu O, Sahin G O, Dudman S G, Said Z N A, Mondelli M U

Liver Int 46(4): e70577, 2026

PMID: 41772850

<https://doi.org/10.1111/liv.70577>

[ウイルス性肝炎制圧におけるワクチンの役割: 欧州 ESGVH からの提言](#)

2026-03-85

Functional study of two flexible regions of the hepatitis E virus ORF1 replicase

Meziere L, Fioulaine S, Montpellier C, Ferrie M, Tubiana T, Vanegas Arias G, Bressanelli S, Cocquerel L, Aliouat-Denis C M

PLoS One 21(3): e0343555, 2026

PMID: 41805850

<https://doi.org/10.1371/journal.pone.0343555>

[HEV ORF1 レプリカーゼの可動領域が担う役割](#)

2026-03-86

Performance evaluation of the Xpert<sup>®</sup> HCV test on fingerstick blood in a prospective observational clinical study at CLIA-waived sites in the United States

Havens J R, Fluker S A, Schimmel J, McCrary L M, Miller L S, Udo T, Manabe Y C, Luetkemeyer A, Burkholder G, Moon A M, Chastain C A, Price J C, Cafardi J, Gallegos-Orozco J F, Young B A, Young J, Aparicio C, Song Y, Lai E, Louw G E

Clin Infect Dis ciag173, Mar 13 [Epub ahead of print]

PMID: 41823658

<https://doi.org/10.1093/cid/ciag173>

[指先採血による Xpert<sup>®</sup> HCV 検査の性能評価: 米国多施設前向き研究](#)

2026-03-87

Relative telomer length as a potential biomarker in hepatocellular carcinoma: a comparative study of HCV patients treated with direct antiviral agent

Helal M, Gamal M, Basuni A A, El Gendy W, Khalil A

BMC Cancer 26:295, 2026

PMID: 41731429

<https://doi.org/10.1186/s12885-025-15339-7>

テロメア長は肝癌の新規バイオマーカーとなるか

2026-03-88

Hepatitis C virus core induces p53 Ser-15 phosphorylation to facilitate E6-associated protein-mediated proteasomal degradation of p53

Yoon H, Park J M, Han J, Kwon Y, Jang K L

Cells 15(5):415, 2026

PMID: 41827849

<https://doi.org/10.3390/cells15050415>

HCV コア蛋白による p53 分解促進の分子機序

2026-03-89

From genome diversity to inferred functional constraints: An integrated evolutionary analysis of hepatitis B virus genotype F

Chacon R D, Marin-Sanchez O, Ango-Bedrinana J, Ango-Aguilar H

Int J Mol Sci 27(5):2284, 2026

PMID: 41828503

<https://doi.org/10.3390/ijms27052284>

HBV(F 型)の進化解析:多様性と機能制約

2026-03-90

Accuracy of diagnostic investigations in monitoring hepatitis B virus infection: Strengths, limitations, and emerging biomarkers

Bozomitu L I, Lupu A, Lupu V V, Gimiga N, Anton Paduraru D T, Mindru D E, Mihai M, Anton C, Anton E, Mitrea M, Adam-Raileanu A, Forna L

Int J Mol Sci 27(5):2464, 2026

PMID: 41828677

<https://doi.org/10.3390/ijms27052464>

HBV 診断検査の精度を見直す: 利点・限界・新規マーカー

2026-03-91

HDV sensing drives USP18-mediated refractoriness to IFN- $\alpha$  response, sparing IFN- $\beta$  /  $\lambda$  in hepatocytes

Eber C, Fouille R, Moehlin J, Juehling F, Casetta P, Chabot E, Bach C, Schuster C, Baumert T F, Lupberger J, Durantel D, Lucifora J, Verrier E R

Antiviral Res 249:106395, 2026

PMID: 41833642

<https://doi.org/10.1016/j.antiviral.2026.106395>

HDV 検知により SP18 を介した IFN- $\alpha$  不応性が誘導されるが、IFN- $\beta$  /  $\lambda$  応答は保たれる

2026-03-92

Diabetes impairs the virological response in patients with chronic hepatitis B: Glycemic control as a key modifiable risk factor

Li A, Han Y, Xiao G, Deng Z, Wen C, Qiu K, He T, Ren H

J Clin Med 15(5):1826, 2026

PMID: 41827243

<https://doi.org/10.3390/jcm15051826>

糖尿病は慢性 B 型肝炎の治療反応を低下させる

2026-03-93

Integrated transcriptomics reveals a SHEV ORF3-mediated circRNA network that disrupts riboflavin metabolism and activates the ko05212 pathway

Luo W, Li J, Wu S, Wang L, Yin Y, Cao X, Wang L, Jiao H

Vet Sci 13(3):253, 2026

<https://doi.org/10.3390/vetsci13030253>

HEV ORF3 を制御する circRNA ネットワークと代謝異常

2026-03-94

Associations of ambient temperature and heat waves with risks of hepatitis E in Jiangsu, China (2010-2023): A time-stratified case-crossover study

Yang L, Wang J, Peng J, Zhang L, Cheng X

Infect Dis Model 11(1):268-77, 2026

PMID: 41278454

<https://doi.org/10.1016/j.idm.2025.10.003>

気温と熱波は E 型肝炎リスクに影響するか(中国江蘇省 2010~2023 年)

2026-03-95

Mitochondrial fusion orchestrated by hepatitis E virus couples pro-viral autophagy and innate immune evasion for efficient replication

Liu X, Jiang Y, Wang C, Li J, Zhang Y, Wang C, Liang Y, Liu H, Yuan J, Wang Y

Free Radic Biol Med 249:260-72, 2026

PMID:41819507

HEV が誘導するミトコンドリア融合と免疫回避機構

2026-03-96

Hepatitis E virus in wild boar from Poland

Didkowska A, Klich D, Matusik K, Di Lecce E, D'Alessio N, Serra F, Levante M, Ptak M, Kwiecien E, Di Bartolo I, De Sabato L, Fusco G, Filip-Hutsch K, Anusz K, Amoroso M G

Sci Rep 026-42235-2, Mar 11 [Epub ahead of print]

PMID: 41813770

<https://doi.org/10.1038/s41598-026-42235-2>

ポーランドのイノシシにおける HEV 感染

2026-03-97

Quantifying the effect of threshold-triggered interventions on hepatitis E virus outbreaks  
Lisitz C

J Theor Biol 112426, Mar 11 [Epub ahead of print]

PMID: 41825657

<https://doi.org/10.1016/j.jtbi.2026.112426>

流行対策のタイミングは重要か:HEV での検証

2026-03-98

Navigating the viral hepatitis drug landscape: New discoveries and enduring challenges. A narrative review

Sun H M, Wang X Y, Xu H Q, Gao Y H

Infect Dis Ther 026-01321-8, Mar 12 [Epub ahead of print] PMID: 41817955

<https://doi.org/10.1007/s40121-026-01321-8>

ウイルス性肝炎治療薬の現在地と課題

2026-03-99

Beyond foodborne HAV: Sexual transmission drives a new wave of cases in Romania

Paun A, Ianache I, Moroti R, Pomohaci G, Tardei G, Youle M, Ruta S, Oprea C

Viruses 18(2):215, 2026

<https://doi.org/10.3390/v18020215>

ルーマニアで拡大する性的感染による A 型肝炎

2026-03-100

Impact of etiological shifts and the rising burden of non-B non-C hepatocellular carcinoma on surveillance and prognosis: Insights from a 20-year retrospective observational study

Yoshimaru Y, Nagaoka K, Setoyama H, Mizuta T, Toyota T, Maeda D, Kurano S, Tanaka K, Inada H, Narahara S, Iio E, Nagaoka M, Nakai Y, Watanabe T, Uoshima H, Tateyama M, Tanaka M, Tanaka Y

Hepatol Res 70161, Mar 18 [Epub ahead of print] PMID:41847941

非 B 非 C 型肝炎細胞癌の病因変化と症例増加が監視と予後に与える影響: 20 年研究

2026-03-101

Suppression of indoleamine 2,3-dioxygenase enhances immune responses to the therapeutic vaccine for chronic hepatitis B

Shirakami Y, Ninomiya S, Ideta T, Kanbe A, Maeda T, Minowa D, Taguchi D, Kubota M, Sakai H, Imai K, Yamamoto Y, Ito H, Saito K, Yoshida O, Hiasa Y, Shimizu M

Hepatol Res 70165, Mar 21 [Epub ahead of print] PMID: 41863789

<https://doi.org/10.1111/hepr.70165>

免疫抑制酵素 IDO の阻害で慢性 B 型肝炎に対する治療ワクチン効果が向上

2026-03-102

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study

Suda G, Ohara M, Baba M, Yamamoto Y, Yoshida S, Fu Q, Yang Z, Hosono H, Yokoyama D, Kitano S, Tanaka T, Meno A, Yasuura N, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ogawa K, Maehara O, Ohnishi S, Izumi T, Yamada R, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N

J Infect 92(4):106715, 2026

PMID: 41763570

<https://doi.org/10.1016/j.jinf.2026.106715>

TAF は免疫抑制下での HBV 再活性化を防ぐ: 24 ヶ月前向き研究

2026-03-103

Impact of metabolic associated steatotic liver disease on antiviral therapy outcomes on chronic hepatitis B patients receiving antiviral therapy

Shiue S J, Ho T H, Lin H Y, Cheng S W, Wu L W, Chan T S, Chen C N, Cheng C L, Lee Y K, Yang H Y, Shiue H S, Leng K F, Wu M S

J Med Virol 98(3): e70864, 2026

PMID: 41848233

<https://doi.org/10.1002/jmv.70864>

MASLD が慢性 B 型肝炎の抗ウイルス治療成績に与える影響

2026-03-104

Pregenomic RNA as a marker for monitoring disease prognosis and viral relapse in hepatitis B patients on long-term antiviral therapy: A systematic review and meta-analysis

Pamarthi J, Panneerselvam S, Rajesh N A, Kumar J S, Haridoss M

J Med Virol 98(3): e70866, 2026

PMID:41854418

pgRNA は B 型肝炎の予後・再燃予測に有用か: 系統的レビューとメタ分析

2026-03-105

Hepatitis D infection: a puzzle still unsolved?

Vitiello A, Boccellino M, Polito G, Zovi A

Virology 619:110879, 2026

PMID:41831423

D 型肝炎はいまだ未解明の疾患か

2026-03-106

Hepatitis D virus: Enigmas and gaps of knowledge

Pujol F H, Jaspe R C, Roca Suarez A A, Batbold E, Zoulim F, Testoni B, Chemin I

Viruses 18(2):244, 2026

<https://doi.org/10.3390/v18020244>

なお多くの謎を残す HDV

2026-03-107

Hepatitis D virus pathogenesis: A sense of complications

Haennel Y, Baumert T F, Lupberger J

Viruses 18(3):278, 2026

<https://doi.org/10.3390/v18030278>

D 型肝炎の病態: 複雑さを読み解く

2026-03-108

Evidence of wild boars as a reservoir of zoonotic hepatitis E virus genotype 3: Implications for public health in Argentina

Williman M M, Colina S E, Di Cola G, Ozaeta D S, Carpinetti B N, Pisano M B, Re V E, Serena M S, Echeverria M G, Metz G E

Pathogens 15(2):205, 2026

<https://doi.org/10.3390/pathogens15020205>

アルゼンチンにおけるイノシシ由来 HEV(3 型)の公衆衛生的意義

2026-03-109

A genetic variant of *TLR6* predicts HBsAg decline after pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B

Zeng W, Wang J, Liang X, Hou J, Chen J, Pan X, Zhou B, Hou J, Jiang D K

J Med Virol 98(3): e70872, 2026

PMID:41823038

[TLR6 遺伝子多型が IFN 治療後の HBs 抗原低下を予測](#)

2026-03-110

HBV RNA predicts the risk of off-treatment relapse in chronic hepatitis B patients with NAs therapy: A systematic review and meta-analysis

Wang D H, Wang J L, Jiang S W, Zhou A W, Jin M H, Zhang H J, Yang S Q, Fan S Y, Hu A R

J Viral Hepat 33(4): e70167, 2026

PMID: 41830105

<https://doi.org/10.1111/jvh.70167>

[NA 治療後の再燃予測における HBV RNA の有用性: 系統的レビューとメタ分析](#)

2026-03-111

Changing pattern of HDV infection in Italy over 40 years; the current scenario and the impending challenge

Caviglia G P, Stroffolini T

J Viral Hepat 33(4): e70172, 2026

PMID: 41841404

<https://doi.org/10.1111/jvh.70172>

[イタリアにおける HDV 感染の 40 年の変遷と今後の課題](#)

2026-03-112

Performance of the ELITE InGenius system for hepatitis B virus DNA quantification

Rosse D, Garrigou O, Ortonne V, Ingiliz P, Leroy V, Pawlotsky J M, Chevaliez S

Diagn Microbiol Infect Dis 114(1):117099, 2026

PMID:40916253

[ELITE InGenius による HBV DNA 定量の性能評価](#)